J3L-MC-EZEB: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3819469 in Adults with Elevated Lipoprotein(a)

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-501426-38-00

Acronym

18547

Enrollment

125

Registered

2023-01-24

Start date

2023-02-09

Completion date

2024-10-04

Last updated

2024-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lipoprotein Disorder

Brief summary

Percent change from baseline in time-averaged Lp(a) over Days 60-180

Interventions

DRUGPlacebo to match LY3819469

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Percent change from baseline in time-averaged Lp(a) over Days 60-180	—

Countries

Denmark, Germany, Netherlands, Romania, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026